WLS-101
Advanced Solid Tumors
Phase 1/2Active
Key Facts
About Waylis Therapeutics
Waylis Therapeutics is a private, clinical-stage biotech leveraging a platform to discover small molecules against challenging protein-protein interaction targets, primarily in oncology. The company has progressed its lead candidate, WLS-101, into Phase 1/2 trials for solid tumors, indicating a transition from research to early clinical development. While its innovative pipeline targets high-value oncology indications, the company also maintains a patient access program for its products, suggesting a hybrid model of development and commercial support. Key risks include the high scientific and clinical hurdles of targeting PPIs, intense competition in oncology, and reliance on funding to advance its pipeline.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |